Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer

Abstract PARP inhibitors (PARPi) have modest antitumor activity in patients with advanced breast cancer and mutation in BRCA. It is unclear whether some subgroups derive greater benefit from treatment. MEDLINE and EMBASE were searched from inception to March 2021 to identify trials of PARPi in patie...

Full description

Bibliographic Details
Main Authors:	A. Desnoyers, M. Nadler, B. E. Wilson, S. Stajer, E. Amir
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-03-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-022-00405-1

Similar Items

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas
by: Nazanin Majd, et al.
Published: (2020-11-01)

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
by: Jiajia Li, et al.
Published: (2023-01-01)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020-03-01)

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017-10-01)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
by: Joseph A. De Soto, Xianyan Wang, Yohei Tominaga, Rui-Hong Wang, Liu Cao, Wenhui Qiao, Cuiling Li, Xiaoling Xu, Amanda P. Skoumbourdis, Sheila A. Prindiville, Craig J. Thomas, Chu-Xia Deng
Published: (2006-01-01)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
by: Andrisha-Jade Inderjeeth, et al.
Published: (2022-11-01)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
by: Daniel Harrision, et al.
Published: (2020-08-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours
by: Faustyna Piędel, et al.
Published: (2020-03-01)

PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer (Russian Translation of Cochrane Plain Language Summary)
by: Karina G. Uvarova
Published: (2022-04-01)

Methods for Purification of Proteins Associated with Cellular Poly(ADP-Ribose) and PARP-Specific Poly(ADP-Ribose)
by: Rood, Jennifer E., et al.
Published: (2014)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
by: Sarkar Oli, et al.
Published: (2009-12-01)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
by: Saman Sargazi, et al.
Published: (2021-09-01)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses.
by: Junqi Song, et al.
Published: (2015-05-01)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
by: Zhimin Zhang, et al.
Published: (2020-01-01)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
by: Stergios Boussios, et al.
Published: (2019-08-01)

Synthesis and study of new 4-quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)
by: Gyozo Kulcsar, et al.
Published: (2003-06-01)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
by: Maurie Markman
Published: (2018-01-01)

The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
by: M. Javle, et al.
Published: (2011-11-01)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
by: Emad Matanes, et al.
Published: (2021-10-01)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
by: Fernet Marie, et al.
Published: (2003-07-01)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
by: Chaowen Shi, et al.
Published: (2023-09-01)

Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review
by: Emilia Nowicka, et al.
Published: (2022-12-01)

Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
by: Felipe Salech, et al.
Published: (2020-08-01)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
by: Aniello Cerrato, et al.
Published: (2016-11-01)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
by: Mathilde Malgras, et al.
Published: (2021-03-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants.
by: Katherine E Zarn, et al.
Published: (2022-01-01)

Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants
by: Katherine E. Zarn, et al.
Published: (2022-01-01)

Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
by: Marine Gilabert, et al.
Published: (2014-01-01)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
by: Ruihong Dong, et al.
Published: (2023-06-01)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
by: Jeanny B Aragon-Ching
Published: (2016-01-01)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
by: Bijay Singh, et al.
Published: (2020-11-01)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
by: Jingsong Zhang
Published: (2014-06-01)

Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
by: Yufeng Wang, et al.
Published: (2014-01-01)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
by: Zongying Gu, et al.
Published: (2019-08-01)

<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
by: Sourat Darabi, et al.
Published: (2022-12-01)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
by: Yingzhu Yang, et al.
Published: (2020-07-01)

Poly (ADP-ribose) Polymerase Promoter Hypermethylation Predispose Females to Breast Cancer
by: Hussein Sabit, et al.
Published: (2019-04-01)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
by: Thomas Helleday, et al.
Published: (2012-12-01)

Poly ADP-ribose polymerase-1: an international molecule of mystery.
by: Woodhouse, B, et al.
Published: (2008)